Table 1.
Direct-acting antivirals currently under development (adapted from Lange and Sarrazin [2012]).
| Drugs name | Phase | |
|---|---|---|
| NS3/4A protease inhibitors | Telaprevir | IV |
| Boceprevir | IV | |
| Simeprevir | III | |
| Faldaprevir | III | |
| Vaniprevir | III | |
| Danoprevir | III | |
| Asunaprevir | III | |
| ABT450 | III | |
| MK-5172 | II | |
| GS-9256 | II | |
| Sovaprevir | II | |
| GS-9451 | II | |
| NS5B polymerase inhibitors | Nucleoside analogue | III |
| Sofosbuvir | II | |
| Mericitabine | II | |
| INX-189 | II | |
| IDX184 | II | |
| ALS-2200 | ||
| Non-nucleoside analogue | II | |
| BI207127 | II | |
| TMC647055 | II | |
| Filibuvir | II | |
| VCH759 | II | |
| VCH916 | II | |
| VX222 | II | |
| Setrobuvir | II | |
| ABT-072 | II | |
| ABT-333 | II | |
| Tegobuvir | II | |
| VX-222 | ||
| NS5A inhibitors | Daclatasvir | III |
| GS-5885 | II | |
| Cyclophilin inhibitors | SCY-635 | III |
| NIM811 | II |